nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—multiple sclerosis—amyotrophic lateral sclerosis	0.709	1	CtDrD
Triamcinolone—PTGS2—amyotrophic lateral sclerosis	0.2	1	CbGaD
Triamcinolone—Personality change—Riluzole—amyotrophic lateral sclerosis	0.00575	0.0861	CcSEcCtD
Triamcinolone—BCHE—diaphragm—amyotrophic lateral sclerosis	0.00451	0.24	CbGeAlD
Triamcinolone—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0443	CcSEcCtD
Triamcinolone—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00196	0.0295	CcSEcCtD
Triamcinolone—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00172	0.0257	CcSEcCtD
Triamcinolone—SERPINA6—hindbrain—amyotrophic lateral sclerosis	0.00171	0.0911	CbGeAlD
Triamcinolone—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0255	CcSEcCtD
Triamcinolone—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0221	CcSEcCtD
Triamcinolone—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0219	CcSEcCtD
Triamcinolone—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00143	0.0759	CbGeAlD
Triamcinolone—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0209	CcSEcCtD
Triamcinolone—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0204	CcSEcCtD
Triamcinolone—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0201	CcSEcCtD
Triamcinolone—PTGS2—appendage—amyotrophic lateral sclerosis	0.00122	0.0651	CbGeAlD
Triamcinolone—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00121	0.0182	CcSEcCtD
Triamcinolone—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.0012	0.018	CcSEcCtD
Triamcinolone—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0175	CcSEcCtD
Triamcinolone—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0173	CcSEcCtD
Triamcinolone—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0165	CcSEcCtD
Triamcinolone—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00109	0.0163	CcSEcCtD
Triamcinolone—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0158	CcSEcCtD
Triamcinolone—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0157	CcSEcCtD
Triamcinolone—NR3C1—nerve—amyotrophic lateral sclerosis	0.001	0.0533	CbGeAlD
Triamcinolone—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000996	0.0149	CcSEcCtD
Triamcinolone—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00098	0.0147	CcSEcCtD
Triamcinolone—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.000946	0.0142	CcSEcCtD
Triamcinolone—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000919	0.0138	CcSEcCtD
Triamcinolone—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000894	0.0134	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.000882	0.0132	CcSEcCtD
Triamcinolone—Injury—Riluzole—amyotrophic lateral sclerosis	0.00087	0.013	CcSEcCtD
Triamcinolone—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000851	0.0128	CcSEcCtD
Triamcinolone—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00083	0.0124	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000826	0.0124	CcSEcCtD
Triamcinolone—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0008	0.012	CcSEcCtD
Triamcinolone—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000787	0.0118	CcSEcCtD
Triamcinolone—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00076	0.0114	CcSEcCtD
Triamcinolone—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000757	0.0114	CcSEcCtD
Triamcinolone—NR3C1—hindbrain—amyotrophic lateral sclerosis	0.00075	0.0399	CbGeAlD
Triamcinolone—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000705	0.0106	CcSEcCtD
Triamcinolone—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000696	0.0104	CcSEcCtD
Triamcinolone—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000691	0.0104	CcSEcCtD
Triamcinolone—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000691	0.0104	CcSEcCtD
Triamcinolone—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000678	0.0102	CcSEcCtD
Triamcinolone—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000665	0.00996	CcSEcCtD
Triamcinolone—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00943	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000607	0.0091	CcSEcCtD
Triamcinolone—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00905	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00905	CcSEcCtD
Triamcinolone—Fluocinolone Acetonide—PLA2G4A—amyotrophic lateral sclerosis	0.000584	0.529	CrCbGaD
Triamcinolone—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00871	CcSEcCtD
Triamcinolone—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000563	0.00844	CcSEcCtD
Triamcinolone—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000556	0.00833	CcSEcCtD
Triamcinolone—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000555	0.00831	CcSEcCtD
Triamcinolone—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000553	0.00829	CcSEcCtD
Triamcinolone—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000549	0.00823	CcSEcCtD
Triamcinolone—SERPINA6—nervous system—amyotrophic lateral sclerosis	0.000514	0.0274	CbGeAlD
Triamcinolone—SERPINA6—central nervous system—amyotrophic lateral sclerosis	0.000495	0.0263	CbGeAlD
Triamcinolone—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000494	0.00741	CcSEcCtD
Triamcinolone—SERPINA6—cerebellum—amyotrophic lateral sclerosis	0.000484	0.0258	CbGeAlD
Triamcinolone—BCHE—brainstem—amyotrophic lateral sclerosis	0.000483	0.0257	CbGeAlD
Triamcinolone—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000472	0.00707	CcSEcCtD
Triamcinolone—NR3C1—embryo—amyotrophic lateral sclerosis	0.000469	0.025	CbGeAlD
Triamcinolone—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00698	CcSEcCtD
Triamcinolone—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000447	0.0067	CcSEcCtD
Triamcinolone—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00044	0.00659	CcSEcCtD
Triamcinolone—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00651	CcSEcCtD
Triamcinolone—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000433	0.00648	CcSEcCtD
Triamcinolone—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000432	0.00647	CcSEcCtD
Triamcinolone—NR3C1—brainstem—amyotrophic lateral sclerosis	0.00043	0.0229	CbGeAlD
Triamcinolone—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00634	CcSEcCtD
Triamcinolone—Cough—Riluzole—amyotrophic lateral sclerosis	0.00042	0.0063	CcSEcCtD
Triamcinolone—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000417	0.00625	CcSEcCtD
Triamcinolone—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000416	0.00623	CcSEcCtD
Triamcinolone—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00614	CcSEcCtD
Triamcinolone—PTGS2—embryo—amyotrophic lateral sclerosis	0.000406	0.0216	CbGeAlD
Triamcinolone—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000405	0.00607	CcSEcCtD
Triamcinolone—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000401	0.00601	CcSEcCtD
Triamcinolone—Fluticasone Propionate—PLA2G4A—amyotrophic lateral sclerosis	0.000399	0.362	CrCbGaD
Triamcinolone—SERPINA6—brain—amyotrophic lateral sclerosis	0.000393	0.0209	CbGeAlD
Triamcinolone—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000393	0.00589	CcSEcCtD
Triamcinolone—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000393	0.00589	CcSEcCtD
Triamcinolone—Infection—Riluzole—amyotrophic lateral sclerosis	0.00039	0.00585	CcSEcCtD
Triamcinolone—Shock—Riluzole—amyotrophic lateral sclerosis	0.000387	0.0058	CcSEcCtD
Triamcinolone—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000384	0.00575	CcSEcCtD
Triamcinolone—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00038	0.00569	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000358	0.00537	CcSEcCtD
Triamcinolone—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00533	CcSEcCtD
Triamcinolone—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00529	CcSEcCtD
Triamcinolone—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00035	0.00525	CcSEcCtD
Triamcinolone—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000346	0.00519	CcSEcCtD
Triamcinolone—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00508	CcSEcCtD
Triamcinolone—BCHE—medulla oblongata—amyotrophic lateral sclerosis	0.000337	0.0179	CbGeAlD
Triamcinolone—Pain—Riluzole—amyotrophic lateral sclerosis	0.000336	0.00504	CcSEcCtD
Triamcinolone—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000324	0.00485	CcSEcCtD
Triamcinolone—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00468	CcSEcCtD
Triamcinolone—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000311	0.00466	CcSEcCtD
Triamcinolone—BCHE—spinal cord—amyotrophic lateral sclerosis	0.0003	0.016	CbGeAlD
Triamcinolone—NR3C1—medulla oblongata—amyotrophic lateral sclerosis	0.0003	0.016	CbGeAlD
Triamcinolone—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00029	0.00434	CcSEcCtD
Triamcinolone—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000282	0.00423	CcSEcCtD
Triamcinolone—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000278	0.00417	CcSEcCtD
Triamcinolone—NR3C1—spinal cord—amyotrophic lateral sclerosis	0.000267	0.0142	CbGeAlD
Triamcinolone—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00026	0.0039	CcSEcCtD
Triamcinolone—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.00026	0.0138	CbGeAlD
Triamcinolone—BCHE—nervous system—amyotrophic lateral sclerosis	0.000253	0.0135	CbGeAlD
Triamcinolone—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00375	CcSEcCtD
Triamcinolone—Rash—Riluzole—amyotrophic lateral sclerosis	0.000248	0.00371	CcSEcCtD
Triamcinolone—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000248	0.00371	CcSEcCtD
Triamcinolone—Headache—Riluzole—amyotrophic lateral sclerosis	0.000246	0.00369	CcSEcCtD
Triamcinolone—BCHE—central nervous system—amyotrophic lateral sclerosis	0.000244	0.013	CbGeAlD
Triamcinolone—BCHE—cerebellum—amyotrophic lateral sclerosis	0.000238	0.0127	CbGeAlD
Triamcinolone—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000233	0.0035	CcSEcCtD
Triamcinolone—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000231	0.0123	CbGeAlD
Triamcinolone—NR3C1—nervous system—amyotrophic lateral sclerosis	0.000225	0.012	CbGeAlD
Triamcinolone—BCHE—Synthesis of PC—CHAT—amyotrophic lateral sclerosis	0.000222	0.0527	CbGpPWpGaD
Triamcinolone—NR3C1—central nervous system—amyotrophic lateral sclerosis	0.000217	0.0115	CbGeAlD
Triamcinolone—NR3C1—cerebellum—amyotrophic lateral sclerosis	0.000212	0.0113	CbGeAlD
Triamcinolone—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000195	0.0104	CbGeAlD
Triamcinolone—BCHE—brain—amyotrophic lateral sclerosis	0.000193	0.0103	CbGeAlD
Triamcinolone—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000188	0.00999	CbGeAlD
Triamcinolone—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000184	0.00976	CbGeAlD
Triamcinolone—NR3C1—brain—amyotrophic lateral sclerosis	0.000172	0.00916	CbGeAlD
Triamcinolone—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00017	0.00907	CbGeAlD
Triamcinolone—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000164	0.00873	CbGeAlD
Triamcinolone—PTGS2—brain—amyotrophic lateral sclerosis	0.000149	0.00793	CbGeAlD
Triamcinolone—NR3C1—Nuclear Receptors—RARA—amyotrophic lateral sclerosis	0.000147	0.0348	CbGpPWpGaD
Triamcinolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—amyotrophic lateral sclerosis	0.00013	0.0308	CbGpPWpGaD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—RARA—amyotrophic lateral sclerosis	0.000116	0.0275	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.000113	0.0267	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.00011	0.0262	CbGpPWpGaD
Triamcinolone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.000109	0.0259	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—SACM1L—amyotrophic lateral sclerosis	9.33e-05	0.0221	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—FIG4—amyotrophic lateral sclerosis	8.77e-05	0.0208	CbGpPWpGaD
Triamcinolone—BCHE—Glycerophospholipid biosynthesis—PLB1—amyotrophic lateral sclerosis	8.61e-05	0.0204	CbGpPWpGaD
Triamcinolone—BCHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—amyotrophic lateral sclerosis	8.17e-05	0.0193	CbGpPWpGaD
Triamcinolone—Betamethasone—PTGS2—amyotrophic lateral sclerosis	7.63e-05	0.0691	CrCbGaD
Triamcinolone—BCHE—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	6.53e-05	0.0155	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	6.05e-05	0.0143	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	6.01e-05	0.0142	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	5.82e-05	0.0138	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—RARA—amyotrophic lateral sclerosis	5.49e-05	0.013	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	5.47e-05	0.013	CbGpPWpGaD
Triamcinolone—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	5.39e-05	0.0128	CbGpPWpGaD
Triamcinolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	5.31e-05	0.0126	CbGpPWpGaD
Triamcinolone—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	5.25e-05	0.0124	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ZNF470—amyotrophic lateral sclerosis	5.03e-05	0.0119	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	4.64e-05	0.011	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	4.55e-05	0.0108	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	4.47e-05	0.0106	CbGpPWpGaD
Triamcinolone—Dexamethasone—PTGS2—amyotrophic lateral sclerosis	4.44e-05	0.0402	CrCbGaD
Triamcinolone—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	4.41e-05	0.0104	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	4.12e-05	0.00976	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	4.03e-05	0.00954	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	3.98e-05	0.00943	CbGpPWpGaD
Triamcinolone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	3.85e-05	0.00913	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ZNF746—amyotrophic lateral sclerosis	3.82e-05	0.00904	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	3.75e-05	0.00888	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	3.75e-05	0.00888	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	3.75e-05	0.00888	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	3.75e-05	0.00888	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	3.64e-05	0.00862	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	3.59e-05	0.00851	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	3.55e-05	0.00842	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	3.53e-05	0.00836	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	3.49e-05	0.00826	CbGpPWpGaD
Triamcinolone—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.49e-05	0.00826	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	3.42e-05	0.0081	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	3.38e-05	0.00802	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	3.38e-05	0.00802	CbGpPWpGaD
Triamcinolone—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	3.36e-05	0.00796	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	3.23e-05	0.00765	CbGpPWpGaD
Triamcinolone—BCHE—Glycerophospholipid biosynthesis—PLA2G4A—amyotrophic lateral sclerosis	3.22e-05	0.00764	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—GRIA2—amyotrophic lateral sclerosis	3.16e-05	0.00748	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	3.06e-05	0.00724	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	3.05e-05	0.00723	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	3.05e-05	0.00722	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	3.02e-05	0.00714	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	3e-05	0.00711	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.82e-05	0.00669	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	2.79e-05	0.00661	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—NEFL—amyotrophic lateral sclerosis	2.79e-05	0.00661	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—CHAT—amyotrophic lateral sclerosis	2.59e-05	0.00614	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	2.59e-05	0.00614	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	2.47e-05	0.00586	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	2.43e-05	0.00576	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	2.42e-05	0.00574	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	2.31e-05	0.00548	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	2.31e-05	0.00547	CbGpPWpGaD
Triamcinolone—BCHE—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	2.25e-05	0.00534	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.25e-05	0.00533	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	2.22e-05	0.00527	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	2.1e-05	0.00498	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.07e-05	0.00489	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—SMN1—amyotrophic lateral sclerosis	2.06e-05	0.00488	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	2.04e-05	0.00483	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	2e-05	0.00475	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	1.94e-05	0.0046	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	1.94e-05	0.00459	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.93e-05	0.00458	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	1.92e-05	0.00455	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	1.9e-05	0.00451	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	1.84e-05	0.00435	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	1.84e-05	0.00435	CbGpPWpGaD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	1.83e-05	0.00432	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	1.74e-05	0.00412	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	1.66e-05	0.00392	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	1.6e-05	0.0038	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—VAPB—amyotrophic lateral sclerosis	1.57e-05	0.00372	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TPK1—amyotrophic lateral sclerosis	1.57e-05	0.00372	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	1.56e-05	0.00369	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	1.48e-05	0.00351	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.47e-05	0.00347	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—IGF1—amyotrophic lateral sclerosis	1.46e-05	0.00345	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—VAPA—amyotrophic lateral sclerosis	1.44e-05	0.00341	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	1.38e-05	0.00327	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	1.36e-05	0.00323	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.34e-05	0.00317	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.33e-05	0.00315	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	1.29e-05	0.00306	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	1.27e-05	0.00302	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—FIG4—amyotrophic lateral sclerosis	1.26e-05	0.00298	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	1.25e-05	0.00296	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	1.19e-05	0.00283	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—FUS—amyotrophic lateral sclerosis	1.18e-05	0.0028	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	1.18e-05	0.00279	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	1.15e-05	0.00272	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—DAO—amyotrophic lateral sclerosis	1.14e-05	0.00269	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.08e-05	0.00256	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.08e-05	0.00256	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	1.04e-05	0.00246	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	1.03e-05	0.00245	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.01e-05	0.00239	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	1.01e-05	0.00238	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	9.9e-06	0.00234	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	9.69e-06	0.0023	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—RARA—amyotrophic lateral sclerosis	9.65e-06	0.00229	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.2e-06	0.00218	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	9.18e-06	0.00218	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	8.68e-06	0.00206	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	8.65e-06	0.00205	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PLB1—amyotrophic lateral sclerosis	8.62e-06	0.00204	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	8.22e-06	0.00195	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	8.12e-06	0.00192	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSR—amyotrophic lateral sclerosis	7.95e-06	0.00188	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	7.83e-06	0.00185	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	7.83e-06	0.00185	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.24e-06	0.00172	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	7.08e-06	0.00168	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CHAT—amyotrophic lateral sclerosis	6.53e-06	0.00155	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	6.31e-06	0.0015	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.25e-06	0.00148	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.17e-06	0.00146	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.08e-06	0.00144	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.96e-06	0.00141	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.93e-06	0.0014	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	5.89e-06	0.00139	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	5.47e-06	0.0013	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.3e-06	0.00126	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.98e-06	0.00118	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	4.73e-06	0.00112	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	4.73e-06	0.00112	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	4.53e-06	0.00107	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.49e-06	0.00106	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	4.32e-06	0.00102	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	4.25e-06	0.00101	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.1e-06	0.000971	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.08e-06	0.000967	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.02e-06	0.000952	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.01e-06	0.000949	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.78e-06	0.000895	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.51e-06	0.000831	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	3.42e-06	0.00081	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	3.29e-06	0.00078	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.23e-06	0.000764	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	2.82e-06	0.000668	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—APOE—amyotrophic lateral sclerosis	2.65e-06	0.000629	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.59e-06	0.000613	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.42e-06	0.000572	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.39e-06	0.000566	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.22e-06	0.000526	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	2.18e-06	0.000517	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.96e-06	0.000465	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.83e-06	0.000433	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.82e-06	0.000431	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.06e-06	0.00025	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.7e-07	0.00023	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	7.98e-07	0.000189	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.47e-07	0.000129	CbGpPWpGaD
